Lv7
3770 积分 2024-08-14 加入
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
16分钟前
待确认
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial
58分钟前
待确认
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
1小时前
待确认
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials
2小时前
待确认
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
2小时前
待确认
Rethinking survival metrics in EGFR-mutated NSCLC: insights from RMST analysis of FLAURA2 and MARIPOSA
24天前
已完结
Next-Generation Multicenter Studies: Using Artificial Intelligence to Automatically Process Unstructured Health Records of Patients with Lung Cancer across Multiple Institutions
29天前
已关闭
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
1个月前
已完结
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
1个月前
已完结
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
1个月前
已完结
皖公网安备34019202002308
